Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosaprepitant - Merck & Co

X
Drug Profile

Fosaprepitant - Merck & Co

Alternative Names: Emend For Injection; Emend IV; Fosaprepitant dimeglumine; IVEmend; MK-0517; MK-517; ONO-7847; Proemend

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiemetics; Fluorinated hydrocarbons; Morpholines; Phosphonic acids; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • No development reported Postoperative nausea and vomiting

Most Recent Events

  • 02 Aug 2022 Launched for Chemotherapy-induced nausea and vomiting (In adolescents, In children, In infants, In neonates) in USA (IV) before August 2022 (Merck & Co pipeline, August 2022)
  • 02 Aug 2022 Registered for Chemotherapy-induced nausea and vomiting (In adolescents, In children, In infants, In neonates) in USA (IV) before August 2022 (Merck & Co pipeline, August 2022)
  • 19 Feb 2021 Launched for Chemotherapy-induced nausea and vomiting in Finland, Denmark, France, Belgium (IV) before February 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top